Nymphai Hyperboreioi

Loxo Continues to Strengthen Its Commitment to Security and Privacy

Retrieved on: 
Tuesday, April 20, 2021
Articles, Privacy, Data security, Social issues, Human rights, Identity management, Nymphai Hyperboreioi, Information security, Medical privacy, Information privacy, Personal data

SOC 2 is one of the most comprehensive evaluations of a company\'s information security controls, attesting to the highest data privacy, data protections and security extent possible.

Key Points: 
  • SOC 2 is one of the most comprehensive evaluations of a company\'s information security controls, attesting to the highest data privacy, data protections and security extent possible.
  • This achievement in security compliance validates Loxo\'s commitment to the confidentiality, integrity, and availability of the data and personal information of its clients and their candidates.\n"We take data privacy and security very seriously at Loxo," said Ilia Cheishvili, Loxo\'s Chief Technology Officer.
  • The certification underscores Loxo\'s commitment to safeguarding customer dataand their candidates\' dataover time.\nThe SOC 2 Type II certifications compliment Loxo\'s established commitment to privacy and security measures Loxo has incorporated into its infrastructure.
  • SOC 2 Type II is an important industry standard, and the highest level of third party security and data privacy auditing possible.

Loxo Announces Expansion into Europe With Dublin Office

Retrieved on: 
Tuesday, April 6, 2021
Nymphai Hyperboreioi, Nymphs

The move to establish strategic business functions in Europe was in response to accommodate soaring demand for Loxo's Talent Intelligence Platform in the EMEA region.

Key Points: 
  • The move to establish strategic business functions in Europe was in response to accommodate soaring demand for Loxo's Talent Intelligence Platform in the EMEA region.
  • The company's new office comes at an ideal time to support Loxo's rapid growth and expansion while taking advantage of the highly skilled labor market in the region.
  • "We're excited to expand our presence outside of North America with our first European office," said Matt Chambers, Loxo's CEO and founder.
  • Learn why more than 4000 recruiting organizations and talent acquisition teams across the globe trust Loxo or for more information, visit Loxo .

Another Top 20 Executive Search Firm Moves to Loxo's State-of-the-Art Talent Intelligence Platform

Retrieved on: 
Monday, September 21, 2020
Articles, Science and technology, Nymphai Hyperboreioi, Nymphs, Artificial intelligence

"Adding the Loxo platform to the search equation gives our team a powerful yet fast tool to elevate that experience."

Key Points: 
  • "Adding the Loxo platform to the search equation gives our team a powerful yet fast tool to elevate that experience."
  • Matt Chambers , CEO, Loxo said, "We are delighted that a firm the caliber of ON Partners has chosen Loxo's Talent Intelligence Platform to run their entire business from end-to-end.
  • Loxo is the #1 Talent Intelligence Platform and global leader in artificial intelligence recruitment automation software.
  • Learn why more than 1350 recruiting organizations and talent acquisition teams across the globe trust Loxo at loxo.co

Loxo Announces Free and Unlimited Personal Contact Information

Retrieved on: 
Tuesday, April 14, 2020
Loxo, Nymphai Hyperboreioi, Proprietary software

DENVER, April 14, 2020 /PRNewswire-PRWeb/ --This week, Loxo announced they will begin offering free and unlimited personal contact information with their proprietary talent graph of 530 million people called Loxo Source.

Key Points: 
  • DENVER, April 14, 2020 /PRNewswire-PRWeb/ --This week, Loxo announced they will begin offering free and unlimited personal contact information with their proprietary talent graph of 530 million people called Loxo Source.
  • Loxo Source is available on all plans, including a completely free plan for first time customers available at Loxo .
  • I'm a happy Loxo customer and haven't been this excited about a recruitment platform ever, but this announcement to offer contact information for free, amongst all 530 million profiles in Loxo Source is a game-changer, pure and simple.
  • Loxo Source boasts a huge reservoir of talent and now free contact finding.

Loxo Launches Game-Changing Recruitment Automation Product Increasing Recruiter Efficiency More Than 500%

Retrieved on: 
Wednesday, March 11, 2020
Loxo, Nymphai Hyperboreioi, BlackBerry PlayBook

DENVER, March 11, 2020 /PRNewswire-PRWeb/ -- This week, Loxo introduced an evolutionary new product called Loxo Outreach.

Key Points: 
  • DENVER, March 11, 2020 /PRNewswire-PRWeb/ -- This week, Loxo introduced an evolutionary new product called Loxo Outreach.
  • Loxo Outreach comes with built in playbook templates to help users get started, and is now available to existing Loxo customers and for all recruiters to try for free by requesting a free account at Loxo .
  • "Loxo Outreach makes best-in-class outreach effortless, automates follow-up, delivers a flawless candidate experience, and drastically reduces time and cost per hire."
  • Loxo is the #1 Talent Intelligence Platform and global leader in Artificial Intelligence Recruitment Automation Software.

Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019

Retrieved on: 
Wednesday, November 6, 2019
Chemical compounds, Organic compounds, Health, Tyrosine kinase inhibitors, Bruton's tyrosine kinase, Eli Lilly and Company, Ibrutinib, LLY, Loxo, Eli Lilly, Nymphai Hyperboreioi, Lilly

INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida.

Key Points: 
  • INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida.
  • The second oral presentation will provide a preclinical analysis of LOXO-305's activity in ibrutinib-resistant CLL, based on patient-derived samples.
  • Finally, a poster presentation will provide a preclinical analysis of LOXO-305's activity against diverse BTK C481 substitution mutations.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.